Zovirax

Chickenpox, Encephalitis, Herpes Simplex, Neutropenia + 18 more

Treatment

20 Active Studies for Zovirax

What is Zovirax

Acyclovir

The Generic name of this drug

Treatment Summary

Acyclovir is an antiviral medication used to treat the herpes virus, including herpes simplex, varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. It is the first line of treatment for all these illnesses and can be prescribed to children as young as six years old. Acyclovir was approved by the FDA in 1982.

Zovirax

is the brand name

image of different drug pills on a surface

Zovirax Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zovirax

Acyclovir

1982

496

Effectiveness

How Zovirax Affects Patients

Acyclovir works by blocking the action of viral DNA polymerase and stopping the replication of herpesviruses. It is considered to be a relatively safe drug with a wide range of therapeutic uses, and it is rare for patients to experience an overdose.

How Zovirax works in the body

Acyclovir works by stopping the virus from replicating its DNA. Acyclovir is converted to an active form in the virus, and then attaches to the virus' DNA polymerase. This attachment prevents the virus from being able to use the polymerase to make more copies of its DNA, stopping the virus from replicating. In some cases, the attachment is so strong that it completely shuts off the virus' DNA polymerase, stopping the virus from replicating completely.

When to interrupt dosage

The suggested measure of Zovirax is contingent upon the diagnosed affliction, including Cytomegalovirus Infections, severe Genital herpes and Herpes simplex type I reactivation. The dosage fluctuates as per the technique of delivery (e.g. Cream - Topical or Injection, powder, lyophilized, for solution - Intravenous) outlined in the following table.

Condition

Dosage

Administration

Bone Marrow Transplant

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Neutropenia

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Simplex Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Chickenpox

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Communicable Diseases

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Immunocompromised

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Genitalis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Shingles

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Keratitis, Herpetic

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Cytomegalovirus Infections

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

prophylaxis of VZV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Genital Herpes

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Herpes Labialis

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Bell Palsy

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Encephalitis, Herpes Simplex

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

prophylaxis of HSV re-activation

200.0 mg, , 400.0 mg, 800.0 mg, 0.05 mg/mg, 200.0 mg/mL, 50.0 mg/mL, 100.0 mg/mL, 5.0 %, 500.0 mg, 1000.0 mg, 50.0 mg, 0.04 mg/mg, 0.03 mg/mg, 25.0 mg/mL

Oral, , Tablet, Tablet - Oral, Capsule, Capsule - Oral, Topical, Cream, Cream - Topical, Ointment, Ointment - Topical, Suspension - Oral, Suspension, Injection, solution - Intravenous, Injection, solution, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Buccal, Tablet, delayed release - Buccal, Ophthalmic, Ointment - Ophthalmic, Tablet - Buccal, Tablet, delayed release, Cutaneous, Ointment - Cutaneous, Kit - Oral; Topical, Kit, Oral; Topical

Warnings

Zovirax Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Acyclovir may interact with Pulse Frequency

There are 20 known major drug interactions with Zovirax.

Common Zovirax Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Acyclovir.

Neomycin

Major

The risk or severity of nephrotoxicity can be increased when Acyclovir is combined with Neomycin.

Procainamide

Major

The excretion of Procainamide can be decreased when combined with Acyclovir.

Tenofovir

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir.

Tenofovir alafenamide

Major

Acyclovir may increase the nephrotoxic activities of Tenofovir alafenamide.

Zovirax Toxicity & Overdose Risk

Overdosing on Furosemide can lead to agitation, coma, seizures, tiredness, and blockage of the kidneys. These symptoms are more likely to occur with high doses and in those with kidney problems. Treatment for Furosemide overdose involves managing symptoms and providing supportive care.

image of a doctor in a lab doing drug, clinical research

Zovirax Novel Uses: Which Conditions Have a Clinical Trial Featuring Zovirax?

34 active trials are currently being conducted to analyze the potential of Zovirax to prevent reactivation of Varicella Zoster Virus, Immunodeficiency and Communicable Diseases.

Condition

Clinical Trials

Trial Phases

Encephalitis, Herpes Simplex

0 Actively Recruiting

Herpes Simplex Infections

0 Actively Recruiting

Herpes Genitalis

0 Actively Recruiting

VZV re-activation

0 Actively Recruiting

Chickenpox

3 Actively Recruiting

Phase 3

Neutropenia

4 Actively Recruiting

Phase 1, Phase 2, Phase 3

Cytomegalovirus Infections

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Bone Marrow Transplant

27 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Keratitis, Herpetic

0 Actively Recruiting

prophylaxis of HSV re-activation

0 Actively Recruiting

Shingles

3 Actively Recruiting

Phase 2, Phase 1

Herpes Simplex

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Genital Herpes

0 Actively Recruiting

prophylaxis of VZV re-activation

0 Actively Recruiting

Bell Palsy

0 Actively Recruiting

Herpes Labialis

0 Actively Recruiting

Zovirax Reviews: What are patients saying about Zovirax?

5

Patient Review

10/29/2017

Zovirax for Recurrent Cold Sore

This treatment is significantly faster-acting than over the counter cold sore treatments.

4.7

Patient Review

7/1/2021

Zovirax for Genital Herpes

This treatment is very effective.

4.7

Patient Review

7/1/2021

Zovirax for Genital Herpes

This treatment is very effective.

4

Patient Review

11/19/2017

Zovirax for Recurrent Cold Sore

I've been using this for years and it really does help to stop or reduce symptoms. However, it does become less effective over time, so if you find that an old tube isn't working as well, get a new one.

3.3

Patient Review

2/18/2012

Zovirax for Recurrent Cold Sore

I apply this product to my lips when needed in order to prevent any cold sore outbreaks. It's not a perfect solution, but it's the best one I've found so far.

2

Patient Review

6/20/2017

Zovirax for Recurrent Cold Sore

Despite being quite expensive, this prescription didn't work for me. Additionally, I had to squeeze the tube extremely hard in order to get any medication out. Not sure if this is because it wasn't filled completely or if they put it in a larger tube to make you think you are getting more.

2

Patient Review

3/9/2014

Zovirax for Recurrent Cold Sore

I tried this twice now, and it really doesn't do anything to speed up the healing process of a cold sore.

2

Patient Review

11/24/2015

Zovirax for Recurrent Cold Sore

This worked great the first time, but since then it's done nothing. I tried it on my sister too and she got the same results.

1.7

Patient Review

8/13/2015

Zovirax for Recurrent Cold Sore

I'm really surprised this ointment has gotten so many good reviews. It clearly doesn't work.

1

Patient Review

2/28/2019

Zovirax for Recurrent Cold Sore

I did not see any results from using this product, and it actually made the situation worse. I stopped using it after a few days and applied an Aloe-based gel instead - which cleared up the issue within four days.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zovirax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Zovirax used to treat?

"The medication Acyclovir is used to treat viral infections such as cold sores, shingles, and chickenpox. In people who experience frequent outbreaks, Acyclovir can help reduce the number of future episodes."

Answered by AI

Do you need a prescription for Zovirax?

"Zovirax Cream is a medication used to treat the symptoms of cold sores and genital herpes. It may be used alone or with other medications. Zovirax Cream belongs to a class of drugs called antivirals."

Answered by AI

Can you buy Zovirax over the counter?

"Acyclovir (Zovirax) is not available over the counter in the United States. It is only available with a prescription. Abreva is a good option if you are looking for an (OTC) medication for cold sores."

Answered by AI

How long does it take Zovirax to work?

"It may take up to two hours for the plasma concentration of acyclovir to peak after it is taken orally. However, the symptoms may only start to reduce after three days. It is best to start taking acyclovir within 48 hours of the first symptoms appearing. Acyclovir should be taken until the full course prescribed is completed."

Answered by AI

Clinical Trials for Zovirax

Image of Princess Margaret Cancer Centre, University Health Network in Toronto, Canada.

Psychoeducation for Caregivers of Bone Marrow Transplant Patients

18+
All Sexes
Toronto, Canada

Background: Caregivers of patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for hematological malignancies face significant challenges that can impact their well-being. This study aims to evaluate the feasibility and acceptability of an adapted psychoeducational intervention(PEI) designed to support these caregivers. Methods: This study will recruit caregivers of alloHCT patients. Participants will be enrolled during pre-transplant clinic visits, typically 2-4 weeks before the scheduled transplant. The intervention consists of eight sessions over 12 weeks, delivered via Microsoft Teams by a nurse facilitator. In the adapted PEI, participants will learn stress management, coping strategies, energy management, goal-setting, communication skills, and support resource access through interactive exercises. Data Collection: Participants will complete questionnaires at three time points: pre-intervention, one month post-transplant, and three months post-transplant. The final assessment will include additional questions about feasibility, acceptability and the initial efficacy of the adapted PEI. Outcomes: The primary outcomes will be the feasibility and acceptability of the adapted psychoeducational intervention (PEI). Secondary outcomes will include initial efficacy of the adapted PEI on caregiver outcomes such as depression, anxiety, satisfaction with caregiving and quality of life. Significance: This research aims to assess the feasibility, acceptability and initial efficacy of implementing the adapted PEI for alloHCT caregivers. If found feasible and acceptable, this intervention could potentially improve caregivers' ability to manage caregiving stressors and pave the way for larger-scale randomized studies and implementation.

Recruiting
Has No Placebo

Princess Margaret Cancer Centre, University Health Network

Samantha Mayo, RN, PhD

Image of Georgetown University School of Medicine in Washington, United States.

Mosaic Website for Blood Cancer Patients

18+
All Sexes
Washington, United States

The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups). The main questions this trial aims to answer are: 1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.

Recruiting
Has No Placebo

Georgetown University School of Medicine (+3 Sites)

Image of University of Kansas Cancer Center in Kansas City, United States.

High Intensity Interval Training for Bone Marrow Transplant

18 - 80
All Sexes
Kansas City, KS

The goal of this clinical trial is to learn how a remotely monitored high-intensity interval training (REMM-HIIT) affects the cardiorespiratory fitness and physical function for patients planning to undergo stem cell transplantation. The main questions it aims to answer are: Is there a change in the participant's cardiorespiratory fitness level? Is there a change in the participant's physical function? Researchers will compare the REMM-HIIT program to a control group of participants who do not take part in the training program to see if REMM-HIIT helps improve stem cell transplantation outcomes. Participants will: * Complete cardiopulmonary exercise testing (CPET) 4 times during the study * Do basic tests to measure physical function 6 times during the study * Answer questions about their life and how they are feeling 6 times during the study * Wear a device to keep track of step counts and heart rate daily * Keep a log of every time they exercise throughout the study * Optionally, provide blood and stool samples 6 times during the study

Waitlist Available
Has No Placebo

University of Kansas Cancer Center (+2 Sites)

Anthony Sung, MD

Have you considered Zovirax clinical trials?

We made a collection of clinical trials featuring Zovirax, we think they might fit your search criteria.
Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Luspatercept for Clonal Cytopenia

18+
All Sexes
New York, NY

The purpose of this clinical trial is to test how well the drug luspatercept works in improving low blood cell counts in people with clonal cytopenias of uncertain significance (CCUS). The main questions the study seeks to answer include: * How many patients experience improvements in their low blood counts (red cells, platelets, or white cells) within 24 weeks, based on specific criteria for blood conditions like myelodysplastic syndromes (MDS)? * How long these improvements last before the condition worsens or changes. * The percentage of participants showing improvements at 12, 24, and 48 weeks. * How long it takes for the condition to progress to more severe diseases like myeloid disorders. * How long red blood cell responses last and how quickly these responses are seen. * The average change in hemoglobin levels over 24 weeks. * How many patients need blood transfusions during the study and how soon transfusions are required. * Changes in participants' well-being and energy levels based on a standardized questionnaire. * Monitoring for any side effects, including progression to MDS or leukemia, heart-related issues, or sudden increases in hemoglobin. Participants will: * Receive luspatercept as an injection every three weeks. * Visit the clinic every three weeks for treatment and monitoring.

Phase 2
Recruiting

Weill Cornell Medical College

Pinkal Desai, MD

Bristol-Myers Squibb

Have you considered Zovirax clinical trials?

We made a collection of clinical trials featuring Zovirax, we think they might fit your search criteria.
Go to Trials
Image of Dana-Farber Cancer Institute in Boston, United States.

Digital Support for Bone Marrow Transplant

18+
All Sexes
Boston, MA

The overall goal of this study is to assess the efficacy of the care.coach Avatar™ in improving anxiety and quality of life for patients undergoing outpatient transplant. After care.coach Avatar™ content and scheduling ("digital intervention" or "program") has been optimized for outpatient allogeneic hematopoietic stem cell transplantation (HCT), a randomized controlled trial (RCT) will be conducted of the digital versus usual supportive care program for outpatient HCT recipients. Potential improvements in anxiety and quality of life will be evaluated, with the intent of increasing comfortability with outpatient transplant and expanding the population of eligible patients willing to receive their transplants in an outpatient setting.

Recruiting
Has No Placebo

Dana-Farber Cancer Institute

Victor Wang, MS

Friendi.fi Corporation

Have you considered Zovirax clinical trials?

We made a collection of clinical trials featuring Zovirax, we think they might fit your search criteria.
Go to Trials